Cargando…

Association of CYP2C9*2 Allele with Sulphonylurea-Induced Hypoglycaemia in Type 2 Diabetes Mellitus Patients: A Pharmacogenetic Study in Pakistani Pashtun Population

Polymorphism in cytochrome P450 (CYP) 2C9 enzyme is known to cause significant inter-individual differences in drug response and occurrence of adverse drug reactions. Different alleles of the CYP2C9 gene have been identified, but the notable alleles responsible for reduced enzyme activity are CYP2C9...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jan, Asif, Saeed, Muhammad, Mothana, Ramzi A., Muhammad, Tahir, Rahman, Naveed, Alanzi, Abdullah R., Akbar, Rani
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452755/ https://www.ncbi.nlm.nih.gov/pubmed/37626778 http://dx.doi.org/10.3390/biomedicines11082282

Ejemplares similares

Evaluation of Type 2 Diabetes Risk Variants (Alleles) in the Pashtun Ethnic Population of Pakistan
por: Jan, Asif, et al.
Publicado: (2021)

Association between Aldosterone Synthase (CYP11B2) Gene Polymorphism and Hypertension in Pashtun Ethnic Population of Khyber Pakhtunkwha, Pakistan
por: Shah, Waheed Ali, et al.
Publicado: (2023)

Validation of Genome-Wide Association Studies (GWAS)-Identified Type 2 Diabetes Mellitus Risk Variants in Pakistani Pashtun Population
por: Jan, Asif, et al.
Publicado: (2022)

Association of HLA-B Gene Polymorphisms with Type 2 Diabetes in Pashtun Ethnic Population of Khyber Pakhtunkhwa, Pakistan
por: Jan, Asif, et al.
Publicado: (2021)

Decoding type 2 diabetes mellitus genetic risk variants in Pakistani Pashtun ethnic population using the nascent whole exome sequencing and MassARRAY genotyping: A case-control association study
por: Jan, Asif, et al.
Publicado: (2023)

Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study
por: van Dalem, Judith, et al.
Publicado: (2016)

Association of APOE (rs429358 and rs7412) and PON1 (Q192R and L55M) Variants with Myocardial Infarction in the Pashtun Ethnic Population of Khyber Pakhtunkhwa, Pakistan
por: Rahman, Naveed, et al.
Publicado: (2023)

Ethnogynaecological Assessment of Medicinal Plants in Pashtun's Tribal Society
por: Adnan, Muhammad, et al.
Publicado: (2015)

Pharmacogenetic Dose Modeling Based on CYP2C19 Allelic Phenotypes
por: Stingl, Julia Carolin, et al.
Publicado: (2022)

Genetic Polymorphism of CYP2C19 in Pakistani Population
por: Riaz, Sana, et al.
Publicado: (2019)

Allelic and genotype frequencies of major CYP2B6 polymorphisms in the Pakistani population
por: Ahmed, Sagheer, et al.
Publicado: (2021)

Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis
por: Salvo, Francesco, et al.
Publicado: (2016)

The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial
por: Al Sifri, S, et al.
Publicado: (2011)

USH2A gene variants cause Keratoconus and Usher syndrome phenotypes in Pakistani families
por: Ahmed, Asif Naveed, et al.
Publicado: (2021)

Epidemiology, Clinico-Pathological Characteristics, and Comorbidities of SARS-CoV-2-Infected Pakistani Patients
por: Omer, Saadia, et al.
Publicado: (2022)

Analysis of Skin Pigmentation and Genetic Ancestry in Three Subpopulations from Pakistan: Punjabi, Pashtun, and Baloch
por: Shan, Muhammad Adnan, et al.
Publicado: (2021)

Acute pharmacogenetic dystonic reactions in a family with the CYP2D6 *41 allele: a case report
por: Wong, Darice Y., et al.
Publicado: (2021)

Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19
por: Swen, J. J., et al.
Publicado: (2011)

The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses
por: Kee, Ping Siu, et al.
Publicado: (2023)

Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics
por: Cacabelos, Ramón, et al.
Publicado: (2012)

Pharmacogenetic Expression of CYP2C19 in a Pediatric Population
por: Pierre-François, Marie Josette Déborah, et al.
Publicado: (2022)

Mutation in Phospholipase C, δ1 (PLCD1) Gene Underlies Hereditary Leukonychia in a Pashtun Family and Review of The Literature
por: Khan, AK, et al.
Publicado: (2018)

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial
por: Chacra, A R, et al.
Publicado: (2009)

MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?
por: de la Torre, Rafael, et al.
Publicado: (2012)

Distribution of alleles, genotypes and haplotypes of the CYP2B6 (rs3745274; rs2279343) and CYP3A4 (rs2740574) genes in the Malian population: Implication for pharmacogenetics
por: Kassogue, Yaya, et al.
Publicado: (2021)

Pharmacogenetics of CYP2A6, CYP2B6, and UGT2B7 in the Context of HIV Treatments in African Populations
por: Ford, Graeme R., et al.
Publicado: (2022)

Genetic Polymorphisms and In Silico Mutagenesis Analyses of CYP2C9, CYP2D6, and CYPOR Genes in the Pakistani Population
por: Ahmed, Shabbir, et al.
Publicado: (2018)

Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the DUAL IV trial
por: Rodbard, H. W., et al.
Publicado: (2016)

Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin‐Induced Cutaneous Adverse Drug Reactions
por: Fohner, Alison E., et al.
Publicado: (2020)

Pharmacogenetics of Long-Term Outcomes of Schizophrenia Spectrum Disorders: The Functional Role of CYP2D6 and CYP2C19
por: Sandhu, Amrit K., et al.
Publicado: (2023)

CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype
por: Helsby, N A, et al.
Publicado: (2008)

Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine
por: Lee, Su-Jun
Publicado: (2013)

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine
por: El Rouby, Nihal, et al.
Publicado: (2018)

In Silico Pharmacogenetics CYP2D6 Study Focused on the Pharmacovigilance of Herbal Antidepressants
por: Don, Charleen G., et al.
Publicado: (2020)

Inter-ethnic genetic variations and novel variant identification in the partial sequences of CYP2B6 gene in Pakistani population
por: Ahmed, Sagheer, et al.
Publicado: (2021)

Effectiveness of sulphonylureas in the therapy of diabetes mellitus type 2 patients: an observational cohort study
por: Wilke, Thomas, et al.
Publicado: (2016)

A spectrum of CYP1B1 mutations associated with primary congenital glaucoma in families of Pakistani descent
por: Rauf, Bushra, et al.
Publicado: (2016)

Hypoglycaemia in Type 2 diabetes
por: Amiel, S A, et al.
Publicado: (2008)

Optimal utilisation of sulphonylureas in resource-constrained settings
por: Naidoo, Poobalan, et al.
Publicado: (2014)

Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function
por: Fohner, Alison E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c01rf490o4d1sre9cejc4ola7a